Please login to the form below
Nektar Therapeutics
This page shows the latest Nektar Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Merck to acquire Pandion Therapeutics for $1.85bn
Merck (MSD) has signed a deal to acquire Pandion Therapeutics for approximately $1.85bn, gaining access to a pipeline of immune modulators for the treatment of autoimmune diseases. ... A number of other pharma companies are also developing IL-2 therapies,
Latest news
-
FDA committee rejects Intellipharmaceutics’ opioid drug Aximris
Verdict closely follows rejection of Nektar’s opioid analgesic. The FDA’s Anesthetic and Analgesic Committee has rejected yet another opioid drug – this time Intellipharmaceutics’ extended-release oxycodone tablet Aximiris. ... Proving the
-
Nektar’s opioid analgesic slammed with FDA panel rejection
Panelists unanimously rejected use of the chronic back pain drug. Nektar Therapeutics has been hit with a unanimous FDA panel rejection of its opioid painkiller, over concerns of drug abuse and ... Although the rejection is a blow to Nektar, the opioid
-
BMS expands collaboration with Nektar, sending shares soaring
Adds research programmes in an additional two cancer types. Bristol-Myers Squibb has expanded its development programme with Nektar, sending shares in the biotech soaring by nearly 20%. ... In addition to the Nektar collaboration and research, BMS has
-
Syncona launches another cell therapy company, Treg specialist Quell
Treg therapy developed by Nektar Therapeutics. ... Similarly, Lilly/Nektar’s NKTR-358 also targets the IL-2 receptor complex to stimulate Treg production.
-
Nektar confirms BMS deal for NKTR-214 is on track
Shares in Nektar rose 10% in the wake of the presentation at JPM healthcare conference. ... Nektar Therapeutics has said the company’s $3.6bn deal with Bristol-Myers Squibb for immuno-oncology drug NKTR-214 won’t be affected by the big pharma’s
More from news
Approximately 3 fully matching, plus 18 partially matching documents found.
Latest Intelligence
-
Cancer immunotherapy: What's on the horizon?
article – but, as recent experience with Incyte and Nektar Therapeutics has shown, not all new drugs and combinations will succeed. ... Nektar Therapeutics’ CD122 agonist NKTR-214 posted mixed results in mid-stage trials alongside Opdivo in solid
-
Deal Watch September 2016
A clinical co-operation between Bristol-Myers Squibb and Nektar Therapeutics was closed under which Opdivo [nivolumab] will be evaluated in combination with Nektar's NKTR-214 in phase I/II ... 639. Cynapsus Therapeutics / Sunovion. Acquisition corporate.
-
Deal Watch June 2016
licence. 230. Moderna Therapeutics/ Merck &Co. mRNA-based personalised cancer vaccines; exclusive for Keytruda combinations (discovery). ... acquisition company. 105. Nektar Therapeutics/ Daiichi Sankyo Europe. Onzeald (etirinotecan pegol), long-acting
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Christian Pangratz to head up Sterna Biologicals
He has also held roles for Nektar Therapeutics, Bayer and Pfizer.
-
Nektar Therapeutics appoints Jeff Ajer
He joins as an independent director. California, US-based Nektar Therapeutics has appointed Jeff Ajer as its independent director to the company’s board of directors, following his 25 years’ of ... Howard Robin, president and CEO, Nektar Therapeutics,
-
Cubist’s Dr Lorianne Masuoka jumps ship to InVivo
Comes amidst MSD’s recent takeover of the antibiotic specialist. InVivo Therapeutics has appointed former Cubist executive team leader Dr Lorianne Masuoka as its new chief medical officer. ... Prior to her time at Cubist, she served in various roles of
More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Roche’s Polivy recommended by NICE for lymphoma therapy
- ASH 2022: bad blood but big advances
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- Eli Lilly announces $450m investment in US manufacturing site
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- EIT Health marks World Cancer Day with €6m pledge for new healthcare delivery models
- World Cancer Day: encouraging men to put their health first
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Strategic behaviour
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- GSK to submit drug application for new antibiotic to US FDA
- EU outlines measures to mitigate antibiotic shortage across Europe
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
PMHub
Page & Page and Partners
For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
